Cervical cancer vaccines could be cost-effective for developing countries, researchers say
Cervical cancer vaccines from Merck and GlaxoSmithKline could be cost-effective if subsidies or new prices are created so developing countries can afford them, researchers said Thursday at the World Cancer Congress in Geneva, Reuters reports.
A vaccine to help prevent cervical cancer is being offered free of charge to girls between the ages of 12 and 18 in Swindon this month.